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Purpose: To evaluate the efficacy and safety of Ahmed glaucoma 
valve (AGV) implantation for glaucomatous eyes in short, 
intermediate, and long term follow up periods.
Patients and Methods: In this retrospective study 76 eyes of 76 
patients who underwent AGV insertion in Imam Hossein Medical 
Center, Tehran, Iran, between January 2008 and March 2017 
with at least three years of followup were included. At each visit 
complete ophthalmic examination was performed and the success 
rate of surgery was assessed. Surgical success  was defined  as 
5 ≤  IOP ≤  21 mmHg  and  at  least  20 %  reduction  in  IOP 
without any glaucoma medication (complete success), or with the 
use of anti glaucoma medications (qualified success). The sum of 
complete and qualified success was reported as cumulative success. 
Results: The mean age of patients was 53.18 ± 16.92 years and 
the mean duration of follow up was 3.27 ± 2.36 years (range: 1-5 
years). The complete surgical success rate was 20 % at 1 year, 18 % 
at 2 years, 16 % at 3 years, 15 % at 4 years, and 8 % at 5 years of 
followup and there was no medication free patient at more than 5 
years followup. The cumulative success rate was 91 %, 88 %, 84 %, 
80 %, and 77 % at 1 to 5 years of followup respectively. 
Conclusion: Ahmed glaucoma valve (AGV) implantation for 
glaucomatous eyes results in acceptable IOP reduction and less 
medication need in short, intermediate, and long term follow up 
periods.
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Introduction
Glaucoma is a leading cause of irreversible 
blindness worldwide 1. Treatment of glaucoma 
is usually performed using drug therapy, but 
in certain conditions like congenital glaucoma, 
poor compliance, lack of awareness, and 
progressive disease, surgical intervention 
becomes the first choice of treatment 2. Various 
surgical approaches have been proposed to treat 
refractory glaucomas such as trabeculectomy, 
cyclodestructive procedures, and glaucoma 
drainage devices 3. Glaucoma drainage 
devices drain aqueous humor from the anterior 
chamber to external subconjunctival space 4,5. 
Indications for implantation of these devices 
include eyes with refractory glaucoma such 
as neovascular glaucoma, uveitic glaucoma, 
glaucoma in aphakia and pseudophakia, 
glaucoma associated with trauma, vitreoretinal 
disorders, penetrating keratoplasty and eyes 
which have failed previous filtration surgery 6,7.
The history of aqueous shunts dates back to 
more than 100 years ago with the use of a 
range of materials to accomplish artificial 
translimbal or transscleral drainage of aqueous 
humor 8,9. 
Various aqueous shunting devices, including 
restrictive and nonrestrictive implants, are 
used to manage complicated glaucoma which 
is resistant to medical therapy and traditional 
filtering surgery. The non-restrictive devices, 
such as Molteno and Baerveldt valves, have 
been associated with the development of 
hypotony after the early postoperative 
period 10,11. The restrictive devices, such as 
Krupin and Ahmed valves, contain a design 
which restricts the flow of aqueous humor to 
eliminate the incidence of hypotony 12,13. The 
Ahmed glaucoma valve (AGV) implant (New 
World Medical, Rancho Cucamonga, CA, 
USA) was introduced to the market in 1993 12. 
The overall success rate of AGV insertion 
varies among different types of glaucomas, 
ranging from 63 % to 100 % at one year of 
follow-up in different case series with different 
success criteria 14,15. Results of the tube versus 
trabeculectomy (TVT) study support the 
expanding use of tube shunts beyond refractory 
glaucomas 16. However, long-term follow-
up data regarding this usage are limited. The 
purpose of the present study was to evaluate 
the short, intermediate and long term (up to 
5 years) efficacy and complications of AGV 
implantation.
Patients and Methods
This retrospective study included 76 patients 
(46 males and 30 females) who had undergone 
AGV insertion at Imam Hossein Medical 
Center, Tehran, Iran, between January 2008 
and March 2017, with at least 3 years of 
follow up. The study design  was approval by 
the  Ethics  Committee  of  Shahid Beheshti 
University  of  Medical  Sciences, Tehran, Iran. 
Best corrected visual acuity (BCVA), IOP 
(measured by calibrated Goldmann applanation 
tonometry), slit lamp biomicroscopy results, 
funduscopic exam results (using 90 diopter 
lens), and the number of glaucoma medications 
and complications were recorded. Surgical 
success was defined as 5 ≤ IOP ≤ 21 mmHg 
and at least 20 % reduction in IOP without 
any glaucoma medication (complete success), 
or with the use of anti glaucoma medications 
(qualified success). The sum of complete and 
qualified success was reported as cumulative 
success. 
Failure was defined as not fulfilling the success 
criteria in two consecutive visits or a need for 
AGV removal or secondary anti glaucoma 
surgery in the follow up period. 
Surgical technique
In all patients, the AGV was implanted in 
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superotemporal quadrant according to the 
same technique. A limbal- basad conjunctival 
flap was fashioned in superotemporal quadrant. 
The AGV (model FP7, New World Medical, 
Rancho Cucamonga, CA, USA) was primed, 
and the plate was secured to the sclera with 
7-0 silk sutures 9 mm behind the limbus and 
inserted into the anterior chamber parallel to 
iris after beveled up trimming. A scleral patch 
graft was sutured as a cover on the tube and 
then the overlying conjunctiva was stitched 
with 10-0 nylon sutures using the running 
method.  Postoperatively,  all  patients  were 
prescribed  chloramphenicol eye drops 4 times 
a day for 1 week  and betamethasone eye 
drops every 2 hours, which was tapered over 
the next 6-8 weeks. Patients were examined 
on the postoperative day 1, then weekly for 
4 weeks, and then every 3 month. IOP lowering 
medication was initiated and continued on 
surgeon decision when the target pressure was 
not gained.
Results
In this retrospective study 76 eyes of 76 
patients (46 male and 30 female) who had 
undergone AGV insertion with at least 3 years 
of follow up were studied. The mean age of 
patients was 53.18 ± 16.92 years and the mean 
duration of follow up was 3.27 ± 2.36 years 
(range: 1-5 years). The mean best corrected 
visual acuity was 1.65 ± 1.07 at the time of 
surgery. Forty one patients were phakic, 
26 patients were pseudophakic and 9 cases 
were aphakic. Table 1 shows the types of 
glaucoma in patients enrolled in the study.
Table 2 shows the mean IOP among patients 
before the surgery and 3 months, 6 months, 
9 months, one year, two years, three year, four 
years, and 5 years postoperatively. The mean 
IOP was significantly lower in all post surgical 
exams up to 5 years. 
Table 3 shows the mean number of medications 
used by patients before the surgery and 3 
months, 6 months, 9 months, one year, two 
years, three years, four years, and 5 years 
postoperatively. The mean number of 
medications was also significantly lower in all 
post surgical exams up to 5 years. 
There was no effect of glaucoma type on 
success rate. The complete surgical success 
rate was 20 % at 1 year, 18 % at 2 years, 16 % 
at 3 years, 15 % at 4 years, and 8 % at 5 years 
of followup and there was no medication free 
patient at more than 5 years followup.  The 
cumulative success rate was 91 %, 88 %, 84 %, 
80 %, and 77 % at 1 to 5 years of followup 
respectively. 
Two patients (2.6 %) needed repeated anti 
glaucoma surgery. Regarding complications 6 
cases with choroidal effusion were observed; 
two cases underwent surgical drainage and 
Table 1: Type of glaucoma in patients 
enrolled in the present study
Glaucoma type 
Description Number Percent
Neovascular glaucoma 23 30 %
Primary open angle 
glaucoma
14 18 %
Complicated cataract 9 12 %
Traumatic 8 11 %
Post vitrectomy 8 11 %
Chronic angle closure 
glaucoma
7 9 %




Congenital cataract 1 1 %
Uveitic glaucoma 1 1 %
Aphakic glaucoma 1 1 %
Sum 76 100 %
Journal of Ophthalmic and Optometric Sciences. Volume 2, Number 4, Autumn 2018. 15
This work is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
four cases improved spontaneously. We also 
had 2 cases of decompensated cornea and 2 
cases of hyphema without AGV failure.
Discussion
The concept of designing a modern drainage 
device for glaucoma control was introduced 
several decades ago 17-21. The role of glaucoma 
drainage devices in controlling glaucoma has 
progressively increased due to improvements 
in design, materials, and manufacturing 
techniques leading to fewer complications 
caused by poor flow control and tissue 
compatibility 22-28. 
The success rate of AGV insertion has been 
reported to be from 63 % to 100 % at one 
year of follow-up in the literature, but there is 
limited knowledge about the long term results 
of this surgery 14-15. In our study we reviewed 
preoperative, intraoperative and postoperative 
information of 76 eyes from 76 patients who 
had undergone AGV insertion and had at 
least 3 years of follow up and observed 91 %, 
88 %, 84 %, 80 % and 77 % of cumulative 
success rate at one to five years respectively. 
In comparison a randomized clinical trial 
conducted by Wilson et al., 29 comparing 
trabeculectomy and AGV implants in patients 
requiring glaucoma surgical intervention with 
or without prior glaucoma surgery reported 
success rates of 83.6 % and 88.1 % at one 
year, respectively. In another retrospective 
Table 2: Comparison of the mean IOP among patients before the surgery and post 
surgical exams up to 5 years
Description Before 
Surgery
3 months 6 months 9 months 1 Year 18 
months
2 Year 3 Year 4 Year 5 Year




















range 40 (14 to 
54)
34 (5 to 
39)
35 (7 to 
42)
36 (7 to 
43)
33 (7 to 
40)
33 (6 to 
39)
34 (8 to 
42)






P value * - 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
N 76 76 76 76 76 76 76 76 41 25
* Wilcoxon Test
Table 3: Comparison of the mean number of IOP lowering medications used by patients 
before the surgery and in post surgical exams up to 5 years
Description Before 
Surgery
3 months 6 months 9 months 1 Year 18 
months
2 Year 3 Year 4 Year 5 Year
















range 4 (0 to 4) 4 (0 to 4) 4 (0 to 4) 4 (0 to 4) 4 (0 to 
4)
4 (0 to 
4)
4 (0 to 4) 4 (0 to 
4)
4 (0 to 
4)
4 (0 to 
4)
P value *  - 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001
N 76 76 76 76 76 76 76 76 41 25
*Chi-Square
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study conducted by Souza et al., 3 long term 
outcomes of AGV insertion in refractory 
glaucoma was evaluated among 78 eyes with 
a minimum of three years of follow up.  They 
reported an 80 % success rate at one year, and 
73 %, 63 %, 54 %, and 49 % success rates at 
two, three, four, and five years, respectively 
3. It seems that our results are better than 
the results reported by Sousa et al., 3 even 
with nearly similar success definitions. The 
probable cause might be inclusion of more 
complicated glaucoma types in their study. In 
Souza et al., 3 study the need for reoperation 
was 5 % which is comparable to our results 
(2.6 %). 
We observed that the mean number of 
medications one year after AVG implantation 
was reduced to 1.82 ± 1.36 drugs. In tube 
versus trabeculectomy study at 1year after 
shunt procedures the mean number of anti-
glaucoma medications was more than 1, which 
is comparable with our results 16. 
The strength of the present study was its long 
term follow-up period up to 5 years while it 
was limited by its retrospective nature and its 
relatively limited number of participants. 
Conclusion
Ahmed glaucoma valve (AGV) implantation 
for glaucomatous eyes results in acceptable 
IOP reduction and less medication need in 
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